Additionally, we also confirmed the strongly and steadily predictive ability of m6A‐DELPFS for glioma patients in multiple other subsets, including primary tumor subset, recurrent tumor subset, IDH wild‐type subset, IDH mutant subset, WHO II‐III subset, WHO IV subset, male subset, female subset, subset with chemotherapy treatment, subset without chemotherapy treatment, subset with radiotherapy treatment, and subset without radiotherapy treatment (Figure 8B,C). This evidence concerns the gene IDH1 and central nervous system cancer.